Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00076362 · ClinicalTrials.gov registry record · Phase 4
Pediatric Hypothalamic Obesity
A Phase 4 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
NCT00076362 is a Phase 4 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 60 participants.
The verdict
NCT00076362, a Phase 4 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
Study Summary
This trial is being conducted in pediatric patients with Hypothalamic Obesity. This generally occurs in people who have had an injury to or tumor in their hypothalamus (gland or organ that secretes hormones). The purpose of this trial is to see how an investigational treatment controls the hormone insulin by lowering the level of insulin in the body resulting in a weight loss in children who are at least 6 years of age but less than 18 years of age. Some children in this trial will receive placebo. To qualify for this study, you and your child's doctor must feel that your child's weight is inadequately controlled within a year from the time of injury to the hypothalamus or tumor of the hypothalamus. This study will help to determine if an investigational treatment is of benefit in controlling a child's weight.
Interventions
- DRUG Sandostatin LAR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2004-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00076362
The ClinicalTrials.gov registry entry for NCT00076362 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sandostatin LAR is the first listed.
NCT00076362 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00076362 about?
NCT00076362 is a clinical study titled "Pediatric Hypothalamic Obesity". This trial is being conducted in pediatric patients with Hypothalamic Obesity. This generally occurs in people who have had an injury to or tumor in their hypothalamus (gland or organ that secretes hormones). The purpose of this trial is to see how an investigational treatment controls the hormone i...
What is the current status of trial NCT00076362?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2004-03.
What interventions are being tested in trial NCT00076362?
The interventions under investigation include: Sandostatin LAR (DRUG).
Who is sponsoring clinical trial NCT00076362?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.